Crossmark

Superdiluted atropine at 0.01% reduces progression in children and adolescents. A 5 year study of safety and effectiveness

Crossref DOI link: https://doi.org/10.1016/j.oftale.2018.02.006

Published Print: 2018-04

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Diaz-Llopis, M.

Pinazo-Durán, M.D.
License Information

Text and Data Mining valid from 2018-04-01
More Information

This article is maintained by: Elsevier

Article Title: Superdiluted atropine at 0.01% reduces progression in children and adolescents. A 5 year study of safety and effectiveness

Journal Title: Archivos de la Sociedad Española de Oftalmología (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.oftale.2018.02.006

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.oftal.2017.12.015

Content Type: article

Copyright: © 2018 Sociedad Española de Oftalmología. Published by Elsevier España, S.L.U. All rights reserved.